Prevalence of Metabolically Associated Fatty Liver Disease in Patients Undergoing Peritoneal Dialysis

Background: Metabolically Associated Fatty Liver Disease (MAFLD) in Chronic Kidney Disease (CKD) patients undergoing renal replacement therapy (RRT) has been reported to have a prevalence of up to 58%. Patients on peritoneal dialysis (PD) have an increased risk for MAFLD due to prolonged exposure to high concentrations of glucosa. The aim of this study is to determine the prevalence of MAFLD in PD patients evaluated using elastography. Methods: Cross-sectional study conducted in adults with CKD on PD, from April to May 2024. Data were collected from medical records and elastography was performed. Data are presented as absolute and relative frequencies, means±SD. Student's t-test and Spearman correlation were performed, with a 95%CI and p-value ≤0.05. Results: 22 patients were included. 82% of the patients exhibited MAFLD, of which 23% showed suggestive data of chronic hepatopathy. No association was found between MAFLD, the use of dialysis solutions, and RRT duration. An association was identified between GGT levels and MAFLD (r=0.51 p= 0.008), with a negative correlation observed with albumin concentrations (r=-0.448 p= 0.01). Daily glucose load was associated with total bilirubin levels (r=0.486 p=0.01), TP (r=0.418 p=0.03), and INR (r=0.408 p=0.03) Conclusion: A high prevalence of MAFLD was identified, higher than reported in other studies, with the presence of advanced fibrosis in a significant percentage of patients, along with the absence of elevation in most serum biomarkers. Therefore, it is necessary to promote screening for MAFLD, supported by imaging studies such as elastography.Demographic characteristics of the population